| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1053553631 |
| P356 | DOI | 10.1016/S0893-133X(98)00066-9 |
| P698 | PubMed publication ID | 9885786 |
| P5875 | ResearchGate publication ID | 13402865 |
| P2093 | author name string | E V Gurevich | |
| J N Joyce | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dopamine | Q170304 |
| P304 | page(s) | 60-80 | |
| P577 | publication date | 1999-01-01 | |
| P1433 | published in | Neuropsychopharmacology | Q2261280 |
| P1476 | title | Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons | |
| P478 | volume | 20 |
| Q44259230 | 7-OH-DPAT and PD 128907 selectively activate the D3 dopamine receptor in a novel environment |
| Q41444993 | A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus |
| Q46881187 | A Ser9Gly polymorphism in the dopamine D3 receptor gene (DRD3) and event-related P300 potentials |
| Q37838858 | Absolute abundances and affinity states of dopamine receptors in mammalian brain: A review |
| Q33652844 | Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence |
| Q40023182 | An association study on the polymorphisms of dopaminergic genes with working memory in a healthy Chinese Han population |
| Q26798235 | Applications of magnetic resonance imaging for treatment-resistant late-life depression |
| Q35669960 | Behavioral sensitization, alternative splicing, and d3 dopamine receptor-mediated inhibitory function |
| Q28828620 | Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design |
| Q48588059 | Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. |
| Q33847160 | Binding of pramipexole to extrastriatal dopamine D2/D3 receptors in the human brain: a positron emission tomography study using 11C-FLB 457. |
| Q43277003 | Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. |
| Q27311205 | Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC. |
| Q34151747 | Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors |
| Q48170494 | Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans |
| Q42141320 | Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model |
| Q36530048 | Cariprazine in the treatment of schizophrenia: a proof-of-concept trial |
| Q35019839 | Case-control association analysis of dopamine receptor polymorphisms in alcohol dependence: a pilot study in Indian males |
| Q48149406 | Challenges in the development of dopamine D2- and D3-selective radiotracers for PET imaging studies. |
| Q58852452 | Chapter I The organization and circuits of mesencephalic dopaminergic neurons and the distribution of dopamine receptors in the brain |
| Q38793660 | Chemical anatomy of pallidal afferents in primates. |
| Q73112575 | Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats |
| Q40563939 | Comparative studies of molecular mechanisms of dopamine D2 and D3 receptors for the activation of extracellular signal-regulated kinase |
| Q38911479 | Computational Study and Modified Design of Selective Dopamine D3 Receptor Agonists. |
| Q37688287 | Connectivity-based functional analysis of dopamine release in the striatum using diffusion-weighted MRI and positron emission tomography |
| Q37807297 | Current perspectives on the selective regulation of dopamine D2 and D3 receptors |
| Q43686158 | D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain |
| Q34349190 | D1 dopamine receptors |
| Q42436871 | D2 antagonist-induced c-fos in an identified subpopulation of globus pallidus neurons by a direct intrapallidal action |
| Q43544209 | D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period |
| Q46740195 | D2-like dopamine receptor-mediated modulation of activity-dependent plasticity at GABAergic synapses in the subthalamic nucleus |
| Q43617477 | D2/D3 dopamine receptor heterodimers exhibit unique functional properties |
| Q34376205 | D3 dopamine receptor, behavioral sensitization, and psychosis |
| Q33692872 | D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics |
| Q35562534 | DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson's disease patients |
| Q47657302 | Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors |
| Q46157390 | Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease |
| Q34512173 | Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect? |
| Q57143927 | Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D receptor agonists |
| Q43687982 | Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins |
| Q57712447 | Discovery of CNS-Like D3R-Selective Antagonists Using 3D Pharmacophore Guided Virtual Screening |
| Q51982840 | Disruption of prepulse inhibition of the startle reflex by the preferential D(3) agonist ropinirole in healthy males. |
| Q28565343 | Distinct regional and subcellular localization of the actin-binding protein filamin A in the mature rat brain |
| Q34277944 | Distribution of dopamine D2-like receptors in the human thalamus: autoradiographic and PET studies |
| Q26864860 | Does a shared neurobiology for foods and drugs of abuse contribute to extremes of food ingestion in anorexia and bulimia nervosa? |
| Q38313013 | Does response inhibition have pre- and postdiagnostic utility in Parkinson's disease? |
| Q34500624 | Dopamine D1 Binding Potential Predicts Fusiform BOLD Activity during Face-Recognition Performance |
| Q34490087 | Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain |
| Q40055792 | Dopamine D2 receptor desensitization by dopamine or corticotropin releasing factor in ventral tegmental area neurons is associated with increased glutamate release |
| Q33718801 | Dopamine D2 receptors and the circadian clock reciprocally mediate antipsychotic drug-induced metabolic disturbances |
| Q36043349 | Dopamine D2/3 receptor antagonism reduces activity-based anorexia |
| Q92225160 | Dopamine D2/D3 receptor abnormalities after traumatic brain injury and their relationship to post-traumatic depression |
| Q28067056 | Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases |
| Q28213652 | Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats |
| Q28259541 | Dopamine D3 receptor antagonists as therapeutic agents |
| Q38071135 | Dopamine D3 receptor antagonists: a patent review (2007 - 2012). |
| Q34386011 | Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs |
| Q36219773 | Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies. |
| Q38057963 | Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia |
| Q39136481 | Dopamine Gene Profiling to Predict Impulse Control and Effects of Dopamine Agonist Ropinirole |
| Q33947433 | Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior |
| Q39620073 | Dopamine agonists and pathologic behaviors |
| Q35751195 | Dopamine in drug abuse and addiction: results from imaging studies and treatment implications |
| Q24644660 | Dopamine receptor gene expression in human amygdaloid nuclei: elevated D4 receptor mRNA in major depression |
| Q82029300 | Dopamine receptor pharmacology |
| Q42835000 | Dopamine system: manager of neural pathways |
| Q43574477 | Dopamine transporter-immunoreactive axons in the mediodorsal thalamic nucleus of the macaque monkey |
| Q44174117 | Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study |
| Q54376223 | Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. |
| Q46881168 | Effect of dopamine D3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats. |
| Q39916831 | Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant |
| Q89927630 | Effects of a dopamine agonist on trusting behaviors in females |
| Q89308612 | Effects of lorcaserin and buspirone, administered alone and as a mixture, on cocaine self-administration in male and female rhesus monkeys |
| Q34356950 | Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNO |
| Q28507054 | Ethanol consumption in mice with a targeted disruption of the dopamine-3 receptor gene |
| Q22253016 | Evaluating dopamine reward pathway in ADHD: clinical implications |
| Q37070133 | Evaluation of N-phenyl homopiperazine analogs as potential dopamine D3 receptor selective ligands. |
| Q48709323 | Evolutionarily conserved organization of the dopaminergic system in lamprey: SNc/VTA afferent and efferent connectivity and D2 receptor expression |
| Q89210445 | Executive functioning and risk-taking behavior in Parkinson's disease patients with impulse control disorders |
| Q37662436 | Exploring the relationship between social attachment and dopamine D2/3 receptor availability in the brains of healthy humans using [11C]-(+)-PHNO. |
| Q33302616 | Expression and distribution of all dopamine receptor subtypes (D(1)-D(5)) in the mouse lumbar spinal cord: a real-time polymerase chain reaction and non-autoradiographic in situ hybridization study |
| Q57138468 | Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry |
| Q42970777 | Extrapyramidal side-effects and dopamine D(2/3) receptor binding in substantia nigra |
| Q35850690 | Extrastriatal D2-like receptors modulate basal ganglia pathways in normal and Parkinsonian monkeys |
| Q34330022 | Extrastriatal dopaminergic circuits of the Basal Ganglia |
| Q48218651 | First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study |
| Q37235240 | Functional Regulation of Dopamine D₃ Receptor through Interaction with PICK1. |
| Q42520187 | Further characterization of preproenkephalin mRNA-containing cells in the rodent globus pallidus |
| Q40462646 | G protein-coupled receptor kinase regulates dopamine D3 receptor signaling by modulating the stability of a receptor-filamin-beta-arrestin complex. A case of autoreceptor regulation. |
| Q24633335 | G protein-coupled receptors in the hypothalamic paraventricular and supraoptic nuclei--serpentine gateways to neuroendocrine homeostasis |
| Q30496315 | Gambling severity predicts midbrain response to near-miss outcomes |
| Q44602611 | Gradient of dopamine responsiveness to dopamine receptor agonists in subregions of the rat nucleus accumbens |
| Q35634676 | Gray-matter volume, midbrain dopamine D2/D3 receptors and drug craving in methamphetamine users. |
| Q37685668 | Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance |
| Q37077658 | High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice. |
| Q47416768 | Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores. |
| Q35892818 | Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis |
| Q43721371 | Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum |
| Q34342432 | Impulsive and compulsive behaviors in Parkinson's disease |
| Q35866876 | In vivo mesolimbic D2/3 receptor binding predicts posttherapeutic clinical responses in restless legs syndrome: a positron emission tomography study |
| Q33636523 | Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. |
| Q44853698 | Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior |
| Q24632803 | Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophrenia |
| Q28584991 | Intensification of the development of ethanol dependence in mice lacking dopamine D(3) receptor |
| Q37430839 | Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa |
| Q34348803 | Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studies |
| Q28573869 | Interactions of GIPC with Dopamine D2, D3but not D4Receptors Define a Novel Mode of Regulation of G Protein-coupled Receptors |
| Q34218028 | Investigating the neurocognitive deficits associated with chronic drug misuse. |
| Q37239341 | Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor |
| Q58176094 | Jeu pathologique chez les patients atteints de la maladie de Parkinson |
| Q47380939 | Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling |
| Q24614563 | Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats |
| Q44207366 | Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors |
| Q48177158 | Management of impulse control disorders in Parkinson's disease. |
| Q64785437 | Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease |
| Q43469689 | Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study |
| Q48493567 | Midbrain dopamine D2/3 receptor binding in schizophrenia |
| Q30490410 | Midbrain dopamine receptor availability is inversely associated with novelty-seeking traits in humans |
| Q37140503 | Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors |
| Q46205987 | Motor impulsivity in Parkinson disease: associations with COMT and DRD2 polymorphisms |
| Q33912549 | Neural activation in the "reward circuit" shows a nonlinear response to facial attractiveness. |
| Q82029336 | Neurochemistry of Parkinson's disease |
| Q30855960 | Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction. |
| Q47596297 | Nigral Stress-Induced Dopamine Release in Clinical High Risk and Antipsychotic-Naïve Schizophrenia |
| Q43738761 | Nigrostriatal collaterals to thalamus degenerate in parkinsonian animal models |
| Q52603588 | Nitric oxide modulates dopaminergic regulation of prepulse inhibition in the basolateral amygdala. |
| Q91964474 | Novel Diels-Alder Type Adducts from Morus alba Root Bark Targeting Human Monoamine Oxidase and Dopaminergic Receptors for the Management of Neurodegenerative Diseases |
| Q37630378 | Novel roles for β-arrestins in the regulation of pharmacological sequestration to predict agonist-induced desensitization of dopamine D3 receptors |
| Q33583797 | Nucleus accumbens core and pathogenesis of compulsive checking |
| Q36480118 | Occupancy of brain dopamine D3 receptors and drug craving: a translational approach. |
| Q24630426 | Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography |
| Q37060818 | PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats |
| Q51797175 | Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation. |
| Q50666702 | Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state. |
| Q48398973 | Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. |
| Q30419672 | Postpartum and depression status are associated with lower [[¹¹C]raclopride BP(ND) in reproductive-age women |
| Q37280384 | Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO |
| Q92046656 | Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia |
| Q28140526 | Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents |
| Q48346301 | Regional and source-based patterns of [11C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D2 and D3 receptor availability in cocaine-use disorder |
| Q48637788 | Regulation of polysynaptic subthalamonigral transmission by D2, D3 and D4 dopamine receptors in rat brain slices |
| Q36497615 | Reversal of dopamine D2 agonist-induced inhibition of ventral tegmental area neurons by Gq-linked neurotransmitters is dependent on protein kinase C, G protein-coupled receptor kinase, and dynamin |
| Q36211286 | Reversal of quinpirole inhibition of ventral tegmental area neurons is linked to the phosphatidylinositol system and is induced by agonists linked to G(q). |
| Q35742020 | Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions. |
| Q22241489 | Role of central dopamine in pain and analgesia |
| Q93336863 | Role of dopamine D2-like receptors and their modulation by adenosine receptor stimulation in the reinstatement of methamphetamine seeking |
| Q24307465 | Roles of protein kinase C and actin-binding protein 280 in the regulation of intracellular trafficking of dopamine D3 receptor |
| Q36226814 | Section II. The dopamine system |
| Q42138992 | Selective D3 Receptor Antagonist SB-277011-A Potentiates the Effect of Cocaine on Extracellular Dopamine in the Nucleus Accumbens: a Dual Core-Shell Voltammetry Study in Anesthetized Rats |
| Q44362504 | Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex |
| Q28191637 | Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior |
| Q91494247 | Selective dopamine D3 receptor antagonist YQA14 inhibits morphine-induced behavioral sensitization in wild type, but not in dopamine D3 receptor knockout mice |
| Q52316241 | Selectivity of probes for PET imaging of dopamine D3 receptors. |
| Q90575790 | Separating dopamine D2 and D3 receptor sources of [11C]-(+)-PHNO binding potential: Independent component analysis of competitive binding |
| Q42700995 | Sex Differences in Midbrain Dopamine D2-Type Receptor Availability and Association with Nicotine Dependence |
| Q35936704 | Signaling mechanisms of the D3 dopamine receptor |
| Q37486897 | Striatal dopamine D2/3 receptor regulation by stress inoculation in squirrel monkeys |
| Q37697439 | Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent mol |
| Q37023517 | Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding characterization at D2/D3 receptors and elucidation of a pharmacophore model. |
| Q36067222 | Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 |
| Q46544589 | Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. |
| Q48252285 | Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R). |
| Q34524556 | Targeting the dopamine D3 receptor: an overview of drug design strategies |
| Q36159207 | The N-terminal region of the dopamine D2 receptor, a rhodopsin-like GPCR, regulates correct integration into the plasma membrane and endocytic routes |
| Q24321785 | The dopamine D(3) receptor Ser9Gly polymorphism modulates prepulse inhibition of the acoustic startle reflex |
| Q30405857 | The dopamine D3 receptor gene and posttraumatic stress disorder. |
| Q28482341 | The effect of chronic antipsychotic drug on hypothalamic expression of neural nitric oxide synthase and dopamine D2 receptor in the male rat |
| Q34512150 | The external globus pallidus: progress and perspectives |
| Q34568242 | The functional DRD3 Ser9Gly polymorphism (rs6280) is pleiotropic, affecting reward as well as movement |
| Q39188526 | The influence of genetic variants on striatal dopamine transporter and D2 receptor binding after TBI. |
| Q33821967 | The interrelationship of dopamine D2-like receptor availability in striatal and extrastriatal brain regions in healthy humans: a principal component analysis of [18F]fallypride binding |
| Q57020898 | The neurobiology of impulsivity and substance use disorders: implications for treatment |
| Q37106827 | The potential role of dopamine D₃ receptor neurotransmission in cognition. |
| Q38650497 | The relationship between subcortical brain volume and striatal dopamine D2/3 receptor availability in healthy humans assessed with [(11) C]-raclopride and [(11) C]-(+)-PHNO PET. |
| Q81860473 | The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence |
| Q90210091 | The role of dopamine D3 receptors in the mechanism of action of cariprazine |
| Q42511791 | The role of the globus pallidus D2 subfamily of dopamine receptors in pallidal immediate early gene expression |
| Q47662557 | The selective dopamine D₃ receptor antagonist SB-277011A attenuates drug- or food-deprivation reactivation of expression of conditioned place preference for cocaine in male Sprague-Dawley rats |
| Q38434642 | Transcriptional signatures of connectomic subregions of the human striatum. |
| Q38639999 | Understanding Peripartum Depression Through Neuroimaging: a Review of Structural and Functional Connectivity and Molecular Imaging Research. |
| Q35554948 | Using click chemistry toward novel 1,2,3-triazole-linked dopamine D3 receptor ligands |
| Q73824879 | Ventral striatal D(3) receptors and Parkinson's Disease |
| Q34982537 | Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. |
| Q53433916 | [18F]fallypride characterization of striatal and extrastriatal D2/3 receptors in Parkinson's disease. |
| Q35599100 | β-arrestin2 plays permissive roles in the inhibitory activities of RGS9-2 on G protein-coupled receptors by maintaining RGS9-2 in the open conformation |
Search more.